Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians
Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, Hennekens CH, Hunter DJ
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 111 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- NCI NIH HHS
- Gobierno
- NIEHS NIH HHS
Según 2 financiadores declarados.
Publicación
- Publicado
- 1998-05-01 · Cancer Epidemiol Biomarkers Prev · vol. 7 · número 5 · págs. 385–90
- Editorial
- National Institutes of Health
- Citado
- 214 citas · más que el 98% de estudios similares · 8.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 35 trabajos
- Acceso
- De pago
- Áreas de investigación
- Vitamin D Research Studies · Prostate Cancer Treatment and Research · Nutrition, Genetics, and Disease
- Palabras clave
- vitamin D receptor, VDR polymorphisms, prostate cancer risk, TaqI polymorphism, BsmI polymorphism, 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D, vitamin D metabolites, age-stratified association, Physicians' Health Study, genetic susceptibility
- MeSH
- humans, prostatic neoplasms, deoxyribonucleases, type ii site-specific, vitamin d, receptors, calcitriol, risk factors, case-control studies, prospective studies, double-blind method, age factors, linkage disequilibrium, polymorphism, genetic, adult, aged, aged, 80 and over, middle aged, physicians, united states, male
8 autores
- Jing Ma🇺🇸Brigham and Women's Hospital; Harvard University
- Meir J. Stampfer
- Peter H. Gann
- Heather Hough
- Edward L. Giovannucci
- Karl T. Kelsey
- Charles H. Hennekens
- D J Hunter
Resumen
El texto original del estudio, en el idioma en que se publicó.
Prostatic cells express vitamin D receptor (VDR), which mediates the functions of 1,25-dihydroxyvitamin D. Two recent case-control studies suggested strong inverse associations between two VDR polymorphisms, TaqI and poly(A), and risk of prostate cancer. These two and a third polymorphism, BsmI, are closely linked. In a case-control study nested in the Physicians' Health Study, a randomized double-blind trial of aspirin and beta-carotene among 22,071 United States male physicians, we examined the associations between BsmI and TaqI and prostate cancer risk and whether the associations varied according to age and vitamin D metabolite levels among 372 incident cases and 591 controls. Among controls, the BB genotype was significantly associated with higher 1,25-dihydroxyvitamin D (median = 36.2 pg/ml for the BB versus 33.9 pg/ml for the bb genotype; P = 0.02), suggesting an association of the VDR polymorphisms with VDR function. Overall, we observed no significant associations of these VDR polymorphisms with prostate cancer risk: relative risk (RR) = 0.86 [95% confidence interval (CI) = 0.57-1.29] for the BB genotype and RR = 0.92 (95% CI = 0.69-1.22) for the Bb genotype, compared with the bb genotype (results were similar for the TaqI polymorphism). Stratification by age ( 61 years) and tumor aggressiveness showed no significant associations. However, in an analysis restricted to men with plasma 25-hydroxyvitamin D below the median, we observed a 57% reduction (RR = 0.43, 95% CI = 0.19-0.98) in risk for those with the BB versus the bb genotype; the risk reduction was particularly marked among older men (RR = 0.18, 95% CI = 0.05-0.68). We did not observe this inverse association among men with 25-hydroxyvitamin D levels above the median, nor did we observe it among younger men.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.